Source: Hepatology/ Official Journal of the American for the Study of Liver Diseases. Conference titles: AASLD Annual Meeting and Postgraduate Courses. Unidade: FM
Subjects: HEPATOPATIAS, GASTROENTEROLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRANDÃO, C. E. et al. Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 18 abr. 2024. , 2002APA
Brandão, C. E., Perez-Gomez, R., Pessoa, M. G., Oliveira-Martinez, M. A., Caramori, C., Bazan-Perez, C. V., et al. (2002). Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo.NLM
Brandão CE, Perez-Gomez R, Pessoa MG, Oliveira-Martinez MA, Caramori C, Bazan-Perez CV, Patelli M, Torres-Ibarra R, Barone A, Dehesa-Violante M, Carrilho F, Vivar R, Tasch F. Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 abr. 18 ]Vancouver
Brandão CE, Perez-Gomez R, Pessoa MG, Oliveira-Martinez MA, Caramori C, Bazan-Perez CV, Patelli M, Torres-Ibarra R, Barone A, Dehesa-Violante M, Carrilho F, Vivar R, Tasch F. Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 abr. 18 ]
